Patents by Inventor Mark S. Dennis

Mark S. Dennis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES
    Publication number: 20200277584
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 3, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Mark S. DENNIS, Jennifer A. GETZ, Anastasia HENRY, Mihalis KARIOLIS, Cathal MAHON, Adam P. SILVERMAN, Ankita SRIVASTAVA, Julie ULLMAN, Junhua WANG, Joy Yu ZUCHERO
  • ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20200223935
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 16, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • ANTI-TAU ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200216522
    Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 9, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
  • Anti-CLL-1 Antibodies and Methods of Use
    Publication number: 20200148774
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Anti-CD3 antibodies and methods of use
    Patent number: 10640572
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
  • Anti-Transferrin Receptor Antibodies and Methods of Use
    Publication number: 20200123267
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • Anti-transferrin receptor antibodies and methods of use
    Patent number: 10508151
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: December 17, 2019
    Assignee: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • Anti-CLL-1 antibodies and methods of use
    Patent number: 10501545
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • TRANSFERRIN RECEPTOR TRANSGENIC MODELS
    Publication number: 20190274291
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Application
    Filed: October 19, 2018
    Publication date: September 12, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero
  • ANTI-APOE ANTIBODIES
    Publication number: 20190270794
    Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
    Type: Application
    Filed: October 27, 2017
    Publication date: September 5, 2019
    Inventors: David Holtzman, Hong Jiang, Fan Liao, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20190112389
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: September 27, 2018
    Publication date: April 18, 2019
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, JR., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU, Liping L. SUN
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20190016823
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 17, 2019
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, JR., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU, Liping L. SUN
  • Anti-CD3 antibodies and methods of use
    Patent number: 10174124
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • Transferrin receptor transgenic models
    Patent number: 10143187
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: December 4, 2018
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero
  • ANTI-CD79b ANTIBODIES AND METHODS OF USE
    Publication number: 20180327492
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Application
    Filed: April 19, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, JR., Andrew Polson
  • TRANSFERRIN RECEPTOR TRANSGENIC MODELS
    Publication number: 20180235195
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Application
    Filed: March 16, 2018
    Publication date: August 23, 2018
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero
  • Anti-CD79b antibodies and methods of use
    Patent number: 9975949
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: May 22, 2018
    Assignee: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, Jr., Andrew Polson
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20180134797
    Abstract: The present invention relates to anti-trans-ferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: November 18, 2015
    Publication date: May 17, 2018
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20180117152
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: December 8, 2017
    Publication date: May 3, 2018
    Inventors: Chingwei Vivian LEE, Mark S. DENNIS, Germaine FUH
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: RE47223
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 5, 2019
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Paul Polakis, William Mallet